Cyclacel Pharmaceuticals Zukünftiges Wachstum
Future Kriterienprüfungen 5/6
Cyclacel Pharmaceuticals is forecast to grow earnings and revenue by 69.9% and 79.1% per annum respectively while EPS is expected to grow by 69.1% per annum.
Wichtige Informationen
69.9%
Wachstumsrate der Gewinne
69.1%
EPS-Wachstumsrate
| Biotechs Gewinnwachstum | 27.1% |
| Wachstumsrate der Einnahmen | 79.1% |
| Zukünftige Eigenkapitalrendite | n/a |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | 23 Oct 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Will Have To Spend Its Cash Wisely
Aug 17
Cyclacel: Trading At Less Than Half Its Cash Value, Near-Term Catalysts, No Obvious Bear Thesis
Aug 07Is Cyclacel Pharmaceuticals (NASDAQ:CYCC) In A Good Position To Invest In Growth?
Apr 15Cyclacel CEO Spiro Rombotis - Addressing Cancer Resistance (Video)
Oct 04Cyclacel issues key business objectives for 2021
Jan 11Cyclacel Pharma inks securities purchase agreement for $7M
Dec 22Cyclacel Pharmaceuticals EPS misses by $1.74
Nov 11Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2026 | 0 | -16 | N/A | N/A | 1 |
| 12/31/2025 | 0 | -15 | N/A | N/A | 1 |
| 12/31/2024 | 0 | -13 | N/A | N/A | 1 |
| 6/30/2024 | 0 | -18 | -12 | -12 | N/A |
| 3/31/2024 | 0 | -20 | -10 | -10 | N/A |
| 12/31/2023 | 0 | -23 | -16 | -16 | N/A |
| 9/30/2023 | 0 | -25 | -17 | -17 | N/A |
| 6/30/2023 | 0 | -24 | -20 | -20 | N/A |
| 3/31/2023 | N/A | -23 | -21 | -21 | N/A |
| 12/31/2022 | N/A | -21 | -21 | -21 | N/A |
| 9/30/2022 | N/A | -19 | -20 | -20 | N/A |
| 6/30/2022 | N/A | -19 | -19 | -19 | N/A |
| 3/31/2022 | N/A | -20 | -22 | -22 | N/A |
| 12/31/2021 | N/A | -19 | -19 | -19 | N/A |
| 9/30/2021 | N/A | -20 | -15 | -15 | N/A |
| 6/30/2021 | N/A | -18 | -11 | -11 | N/A |
| 3/31/2021 | N/A | -15 | -9 | -9 | N/A |
| 12/31/2020 | N/A | -12 | -8 | -8 | N/A |
| 9/30/2020 | N/A | -8 | -8 | -8 | N/A |
| 6/30/2020 | N/A | -8 | -8 | -8 | N/A |
| 3/31/2020 | N/A | -7 | -9 | -9 | N/A |
| 12/31/2019 | N/A | -8 | -9 | -9 | N/A |
| 9/30/2019 | 0 | -8 | -10 | -10 | N/A |
| 6/30/2019 | 0 | -8 | -9 | -9 | N/A |
| 3/31/2019 | 0 | -8 | -8 | -8 | N/A |
| 12/31/2018 | 0 | -7 | -7 | -7 | N/A |
| 9/30/2018 | N/A | -8 | -7 | -7 | N/A |
| 6/30/2018 | N/A | -14 | -7 | -7 | N/A |
| 3/31/2018 | N/A | -15 | N/A | -6 | N/A |
| 12/31/2017 | N/A | -15 | N/A | -7 | N/A |
| 9/30/2017 | 0 | -16 | N/A | -8 | N/A |
| 6/30/2017 | 0 | -10 | N/A | -10 | N/A |
| 3/31/2017 | 1 | -11 | N/A | -11 | N/A |
| 12/31/2016 | 1 | -12 | N/A | -10 | N/A |
| 9/30/2016 | 1 | -13 | N/A | -10 | N/A |
| 6/30/2016 | 1 | -12 | N/A | -11 | N/A |
| 3/31/2016 | 2 | -13 | N/A | -13 | N/A |
| 12/31/2015 | 2 | -15 | N/A | -14 | N/A |
| 9/30/2015 | 2 | -16 | N/A | -15 | N/A |
| 6/30/2015 | 2 | -18 | N/A | -18 | N/A |
| 3/31/2015 | 2 | -20 | N/A | -19 | N/A |
| 12/31/2014 | 2 | -20 | N/A | -19 | N/A |
| 9/30/2014 | 2 | -18 | N/A | -20 | N/A |
| 6/30/2014 | 1 | -19 | N/A | -16 | N/A |
| 3/31/2014 | 1 | -13 | N/A | -18 | N/A |
| 12/31/2013 | 1 | -20 | N/A | -18 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: CYCC is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.5%).
Ertrag vs. Markt: CYCC is forecast to become profitable over the next 3 years, which is considered above average market growth.
Hohe Wachstumserträge: CYCC is expected to become profitable in the next 3 years.
Einnahmen vs. Markt: CYCC's revenue (79.1% per year) is forecast to grow faster than the US market (8.9% per year).
Hohe Wachstumseinnahmen: CYCC's revenue (79.1% per year) is forecast to grow faster than 20% per year.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: Insufficient data to determine if CYCC's Return on Equity is forecast to be high in 3 years time